Review



excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody
    Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) <t>ERCC1</t> mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.
    Excision Repair Cross Complementation Group 1 Ercc1 Rabbit Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody/product/Proteintech
    Average 93 stars, based on 29 article reviews
    excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells."

    Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.

    Journal: Molecular medicine reports

    doi: 10.3892/mmr.2018.9730

    Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.
    Figure Legend Snippet: Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

    Techniques Used: Gene Expression, Standard Deviation, Western Blot, Expressing, Control, Polymerase Chain Reaction



    Similar Products

    excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody  (Proteintech)
    93
    Proteintech excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody
    Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) <t>ERCC1</t> mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.
    Excision Repair Cross Complementation Group 1 Ercc1 Rabbit Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    excision repair cross complementation group 1 ercc1 rabbit polyclonal antibody - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    excision repair cross-complementation 1 (ercc1) rabbit polyclonal antibody  (Proteintech)
    90
    Proteintech excision repair cross-complementation 1 (ercc1) rabbit polyclonal antibody
    Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) <t>ERCC1</t> mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
    Excision Repair Cross Complementation 1 (Ercc1) Rabbit Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/excision repair cross-complementation 1 (ercc1) rabbit polyclonal antibody/product/Proteintech
    Average 90 stars, based on 1 article reviews
    excision repair cross-complementation 1 (ercc1) rabbit polyclonal antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

    Journal: Molecular medicine reports

    Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.

    doi: 10.3892/mmr.2018.9730

    Figure Lengend Snippet: Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

    Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586‐1‐AP) and TYMS rabbit polyclonal antibody (cat. no. 15047‐1‐AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

    Techniques: Gene Expression, Standard Deviation, Western Blot, Expressing, Control, Polymerase Chain Reaction

    Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

    Journal: Molecular Medicine Reports

    Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells

    doi: 10.3892/mmr.2018.9730

    Figure Lengend Snippet: Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

    Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586-1-AP) and TYMS rabbit polyclonal antibody (cat. no. 15047-1-AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

    Techniques: Gene Expression, Quantitative RT-PCR, Standard Deviation, Western Blot, Expressing, Control, Reverse Transcription, Real-time Polymerase Chain Reaction